Neurocrine Biosciences Acquires Soleno Therapeutics in $2.6 Billion Cash Deal

Neurocrine Biosciences is making a major strategic move, acquiring Soleno Therapeutics in an all-cash transaction valued at approximately $2.6 billion. The deal, priced at $53 per share, represents a significant premium and immediately shifts the competitive landscape for rare disease treatments. This acquisition is not just a financial transaction; it’s a direct play for control of Soleno’s lead asset, diazoxide choline, a potential first-in-class therapy for Prader-Willi syndrome (PWS), a severe genetic disorder with no approved treatments.

The acquisition centers on securing full rights to diazoxide choline (DCCR), which recently reported positive top-line results from its Phase 3 trial. Neurocrine is betting heavily on this late-stage asset to immediately bolster its neuroscience and endocrine pipeline. The $53 per share offer is a 150% premium over Soleno’s 30-day volume-weighted average price, signaling Neurocrine’s high conviction in the drug’s commercial potential and its urgency to lock in the asset ahead of potential regulatory milestones.

This move places immediate pressure on other developers in the rare endocrine and genetic disorder space, particularly those targeting PWS. For Neurocrine, the deal diversifies its revenue base beyond its flagship movement disorder drugs and accelerates its push into high-need, specialty markets. The all-cash structure suggests a strong balance sheet and a desire for a swift, clean integration to fast-track DCCR’s path to market, pending regulatory review. The transaction’s success now hinges on the final FDA approval and commercial execution for this first potential therapy for Prader-Willi syndrome.